Arcadia Biosciences, Inc. AGM 2026

Review the key takeaways and the transcript of this earnings call.

PeriodFY 2026Duration12 min

Key takeaways

Gregory Waller was elected as a Class 2 director to serve until the 2029 annual meeting of stockholders or until his successor is duly elected and qualified.
The issuance proposal for common stock upon exercise of Series A1 preferred investment options sold in a private placement transaction closed on June 12, 2026, was approved by a majority of votes cast.
The 2026 omnibus equity incentive plan was approved by a majority of votes cast.
The proposal to amend the certificate of incorporation to allow a reverse stock split of common stock at a ratio ranging from 1:2 to 1:10 before June 30, 2027, was approved by a majority of votes cast.
The non-binding advisory vote to approve the compensation of the company's named executive officers was approved by a majority of votes cast.
The ratification of Ramirez Jimenez International CPAs as independent auditors for the fiscal year ending December 31, 2026, was approved by a majority of votes cast.
The proposal to adjourn the meeting to a later date if necessary to permit further solicitation and vote of proxies was approved by a majority of votes cast.
No questions were received from stockholders during the meeting.

StockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.

Keep exploring

More recent earnings calls